Yarrow Bioscience Inc (YARW) News
Follow Yarrow Bioscience Inc (YARW) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 5 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Yarrow Bioscience, Inc. (“Yarrow” or the “Company”) (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases, today announced the closing of it
EQUITY | Sep 14, 2026, 08:05 PM UTC
L
Yarrow Bioscience Raises About $161.8 Million in Public Stock Offering at $26 Per Share
Yarrow Bioscience entered into an Underwriting Agreement to sell 5,769,231 shares of common stock at $26.00 per share, with underwriters exercising in full a 30-day option for 865,384 additional shares. Net proceeds are
EQUITY | Sep 14, 2026, 08:04 PM UTC
M
Yarrow Bioscience prices $150M common stock offering at $26
Yarrow Bioscience priced an underwritten public offering of 5.77M shares at $26.00 per share, targeting about $150M in gross proceeds, with a 30-day option for up to 865,384 additional shares.
EQUITY | Sep 11, 2026, 07:11 AM UTC
L
Yarrow Bioscience commences proposed underwritten public offering
Yarrow Bioscience, Inc. (Nasdaq: YARW) said it has commenced an underwritten public offering of shares of its common stock, or in lieu thereof, such other securities as described in the offering terms.
EQUITY | Sep 10, 2026, 08:03 PM UTC
L
YARW new Buy @ TDCowen
YARW new Buy @ TDCowen
EQUITY | Jul 28, 2026, 11:33 AM UTC